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Abstract
The presence of the translocator protein (TSPO), previously named as the mitochondrial or peripheral benzodiazepine
receptor, in bone cells was studied in vitro and in situ using RT-qPCR, and receptor autoradiography using the selective TSPO
ligand PK11195. In vitro, the TSPO is highly expressed in osteoblastic and osteoclastic cells. In situ, constitutive
expression of TSPO is found in bone marrow and trabecular bone, e.g., spongiosa. Mice with a reduction of bone turnover
induced by a 4-day treatment of osteoprotegerin reduces [3H]PK11195 binding in the spongiosa (3206128 Bq.mg21,
4996106 Bq.mg21 in saline-treated controls). In contrast, mice with an increase in bone turnover caused by a 4-day low
calcium diet increases [3H]PK11195 binding in the spongiosa (615690 Bq.mg21). Further, our study includes technical
feasibility data on [18F]fluoride microPET imaging of rodent bone with altered turnover. Despite [18F]fluoride having high
uptake, the in vivo signal differences were small. Using a phantom model, we describe the spillover effect and partial
volume loss that affect the quantitative microPET imaging of the small bone structures in experimental mouse models. In
summary, we demonstrate the expression of TSPO in small rodent bone tissues, including osteoblasts and osteoclasts. A
trend increase in TSPO expression was observed in the spongiosa from low to high bone turnover conditions. However,
despite the potential utility of TSPO expression as an in vivo biomarker of bone turnover in experimental rodent models, our
small animal PET imaging data using [18F]fluoride show that even under the condition of a good biological signal-to-noise
ratio and high tracer uptake, the currently achievable instrument sensitivity and spatial resolution is unlikely to be sufficient
to detect subtle differences in small structures, such as mouse bone.
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Introduction
The peripheral or mitochondrial benzodiazepine receptor
[1,2,3,4], also referred to as the translocator protein (TSPO) [5],
is an 18kDa intracellular protein expressed in many tissues and
tends to be up-regulated in conditions of immune stimulation,
stress responses as well as increased cell turnover and tissue
damage [2,4,6,7]. The latter most likely relates to the prominent
expression of the TSPO in cells of mononuclear phagocyte lineage
[7,8]. While the TSPO expression has been found in human
osteoblast cultures [9], its expression in osteoclasts or in bone tissue
in differing states of turnover has not yet been reported.
There is broader interest in the TSPO as an in vivo imaging
marker of active tissue pathology. One well characterised TSPO-
selective radioligands suitable for positron emission tomography
(PET) is 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-1-iso-
quinoline carboxamide ([11C]PK11195) [10,11]. It has been used
to image active tissue pathology in the human central nervous
system, by virtue of the prominent expression of TSPO in activated
microglia, the brain intrinsic macrophage population [12,13,14,15].
In this study, we examined the expression of TSPO in mouse
primary bone cultures and bone tissues with altered turnover rates.
In addition, we investigated the feasibility of microPET, i.e. small
animal positron emission tomography, to quantify altered bone
turnover in vivo using [18F]fluoride as a benchmark radiotracer
with high uptake and good signal-noise ratio.
Materials and Methods
Animal ethical approval was obtained for the experiments
reported in this study: Approved by the South West Area Health
Service Area Health Service Animal Welfare Committee -
Approval number 2005/010A (Title: Bone Imaging in rats and
mice by micro-PET) and by the University of Sydney Animal
Ethics Committee – Approval number A41/11-2005/3/4196
(Title: Bone Imaging in rats and mice by micro-PET).
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Mouse models of altered bone turnover
Five-week old CD-1 mice were maintained on a normal diet for
1 week prior to any treatment. At this time, the mice were
randomized on Day 0 into low bone turnover, high bone turnover
or normal groups.
Low bone turnover was produced in mice on a normal diet by
administering a single subcutaneous injection (5 mg/kg on Day 0)
of a recombinant construct of osteoprotegerin (OPG) containing
amino acids 22–194 of human OPG fused to the Fc domain of
human immunoglobin G (Fc-OPG) (kindly provided by Amgen,
Inc., Thousand Oaks, CA, U.S.A.). This dose of long-acting Fc-
OPG has been previously shown to inhibit bone resorption
profoundly and to reduce bone turnover for this period of study
[16].
High bone turnover was induced using dietary calcium
restriction as previously reported [17]. In brief, mice were
provided with a commercially-available low calcium diet (Specialty
Feeds, Glen Forrest, WA, Australia) from Day 0 – calcium content
was reduced to 0.1 g/100 g whereas the calcium content in the
normal mouse diet was 0.6 g/100 g. The diet was in the form of
12 mm diameter pellets. These mice also received a subcutaneous
injection of saline on Day 0 to assure direct comparability with the
low bone turnover mice.
Control mice were mice on a normal diet with subcutaneous
injection of saline on Day 0.
On day 4, the treated mice were used for microPET study (mice
with OPG or low calcium diet treatment only, N = 4/group), or
were euthanized by cervical dislocation either for film autoradi-
ography study (all 3 types of mouse models, N = 4/group) or RNA
extraction and RT-qPCR (1 control mouse).
Primary osteoblast and osteoclast culture
Primary osteoblastic cells were prepared from the calvaria of
newborn CD-1 mice by digestion with 0.1% collagenase
(Worthington Biomedical Co., Lakewood, NJ, U.S.A.) and 0.2%
dispase (Invitrogen, Carlsbad, CA, U.S.A.). Cells were cultured in
24-well plates at a density of 105 cells/well in alpha-minimum
essential medium (a´MEM; Invitrogen, Carlsbad, CA, U.S.A.)
containing 10% fetal bovine serum (FBS). Cells were allowed to
attach for 24 hours, and then media were replaced with a´MEM
containing 10% FBS, ascorbic acid (50 mg/ml; Sigma Aldrich) and
aˆ-glycerophosphate (10 mM; Sigma Aldrich). Cells were cultured
for a further 7 days with fresh medium replacement every 2 days.
Mouse spleen cells were obtained from 6 week-old CD-1 mice
and cultured for 7 days in a´MEM containing 10% FBS, 25 ng/ml
macrophage colony-stimulating factor (M-CSF; R&D Systems,
Minneapolis, MN, U.S.A.), and 50 ng/ml receptor activator of
nuclear factor kb ligand (RANKL) (R&D Systems, Minneapolis,
MN, U.S.A.) for 7 days with fresh medium replacement every 2
days.
RNA isolation, reverse transcription and real-time PCR
The femurs and tibias of 1 control mouse were harvested. After
the muscles were carefully removed, the bone tissues (,100 mg
each) were snap frozen in liquid nitrogen then used immediately
for RNA extraction. Total RNA was isolated from mouse bone
tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, U.S.A.), or
from cultured osteoblasts and osteoclasts using NucleoSpinH RNA
II Kit (Macherey-Nagel, Du¨ren, Germany) following the manu-
facturers’ protocols. TSPO mRNA expression has been reported
in skeletal muscle [18], thus RNA extraction was also performed
for some of the mouse skeletal muscles which were to be used as
positive control in the present study. The concentration of the
RNA was determined using the BioPhotometer (Eppendorf,
Hamburg, Germany). The purity of the extracted RNA was
assessed spectrophotometrically using the A260/A280 ratio, while
RNA integrity was assessed by the 28s/18s ratio after electropho-
resis on 1% agarose gel.
First strand cDNA was synthesized from 2 mg of total RNA
using the SuperScriptH III First-Strand Synthesis Super Mix kit
(Invitrogen, Carlsbad, CA, U.S.A.) according to the manufactur-
er’s instruction. The freshly prepared cDNA was further diluted by
DEPC-treated water and the subsequent real-time PCR was
performed by CFX 384TM Real-Time PCR Detection System
using SsoFast supermix (BioRad, California, U.S.A.). Bone
markers i.e. alkaline phosphatase (ALP) for osteoblast [19] and
tartrate resistant acid phosphatase (TRAP) for osteoclast [20], as
well as TSPO mRNA expression levels in the above primary cell
cultures and bone tissues were investigated (For PCR primer
sequences, see Table S1). The annealing temperature was
empirically optimized so as to accommodate all the PCR primers
in a single run. The PCR conditions were 98uC for 30 seconds,
followed by 45 cycles at 98uC for 5 seconds, 60uC for 10 seconds.
At the end of the 45th cycle, the temperature was raised to 72uC
for 10 minutes to ensure complete extension of the PCR products.
A melt curve analysis was performed after the PCR to confirm the
specificity of the results. Another PCR without the melt curve
analysis was performed using TSPO primer on the whole bone
tissue only and the PCR product was used for restriction enzyme
assay (see below).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [21]
(Table S1) was used as internal standard. The relative expressions
of target genes were quantified using comparative Ct analysis
incorporated in the CFX ManagerTM Software (version 1.5)
(BioRad, California, U.S.A.).
Restriction enzyme assays and DNA sequencing
Two types of restriction enzymes were used for digesting the
PCR products amplified from the TSPO primers: (1) the blunt
ends PvuII (BioLabs Inc., Ipswich, MA, U.S.A.), cutting at
nucleotide position 202; (2) the sticky ends NcoI (BioLabs Inc.,
Ipswich, MA, U.S.A.), cutting site at 114/118. Digestion was
performed for 1.5 hours at 37uC. The digests were visualized on
1.5% agarose gel by ethidium-bromide staining.
In order to further confirm the specificity of the results, some of
the undigested PCR products were purified using the purification
kit NucleoSpin H Extract II (Macherey-Nagel Inc., Bethlehem, PA,
U.S.A.) and sent to the Sydney University Prince Alfred
Macromolecular Analysis Centre for DNA sequencing.
Film autoradiography using [3H]PK11195
The femurs from the control mice and mice with high or low
bone turnover (N = 4/group) were decalcified in 10% EDTA for
7 days before tissue sectioning. Cryostat bone sections (10 mm)
were placed onto superfrost slides (Menzel-Glaser, Braunschweig,
Germany) and stored in the dark at 220uC for no longer than 1
week before the experiment. The film autoradiography was
performed according to the established method [12,22] using R-
[N-methyl-3H] PK11195 ethanol solution, with a specific activity
of 3.14 TBq.mmol21 (PerkinElmer, Waltham, Massachusetts,
U.S.A.). Tritium standards (Amersham Biosciences, Uppsala,
Sweden) co-exposed with the bone sections on each Hyper-
film-3H (Amersham Biosciences, Uppsala, Sweden) at 4uC for 14
days, were used to quantify the autoradiographically measured
binding.
The hyperfilm was developed using Kodak GBX developer and
fixer (Sigma Aldrich, St. Louis, MO, U.S.A.). The hyperfilm was
air-dried overnight before being scanned using the ArtixScan
Translocator Protein Expression in Bone Tissues
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1800f flatbed scanner (Microtek, Hsinchu, Taiwan), with greyscale
using a magnification of 400% and an optical resolution of 2400
pixels per inch. No pre-scanning manipulation or filter was
applied.
The film-autoradiographic quantification of [3H]PK11195
binding indicating regional TSPO receptor expression was
performed on the scanned hyperfilms using ImageJ (freeware by
Wayne Rasband, National Institutes of Health, U.S.A.) without
Figure 1. Steps for defining the sub-growth plate spongiosa as the ROI in a bone autoradiograph. (A) The growth plate is readily
identified as a landmark. (B) shows the consistent expansion of 400 mm around the initially defined landmark structure of the growth plate (C) and
the resultant delineation of the sub-growth plate spongiosa.
doi:10.1371/journal.pone.0030623.g001
Figure 2. MicroPET tomogram of a mouse skeleton. (A) shows the placement of the ROI on femur bone in the sagittal plane where it is a clearly
delineated circular area (indicated by white arrows). The elongated structure in the last 8 planes of the image is the spinal column. (B) shows a
coronal plane of an OPG-treated mouse microPET tomogram. The bright spot at the pelvic level is the bladder.
doi:10.1371/journal.pone.0030623.g002
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further image processing, such as contrast variation or background
subtraction. On film-autoradiographic images of the bone, the
growth plate imposes as a readily identifiable structure of high
contracts. It can, therefore, be used as a robust anatomical
landmark to place a region of interest (ROI) for quantification of
the level of receptor binding in a defined area of the spongiosa of
the bone. The ROI, i.e. the spongiosa, which is directly adjacent to
the growth plate, was defined by a semi-automated process
consistently applied to all samples as shown in Figure 1. It involves
as the only manual procedure the delineation of the anatomical
landmark (Figure 1A), i.e. the growth plate to serve as the kernel
expansion of a 400 mm perimeter around the landmark outline
Figure 3. The gelatin phantom to simulate partial volume loss and spillover effect in vivo. The dashed line represents the centre of the
microPET axial field of view and is positioned 4 mm from the interface between the region containing 8 MBq and the region containing 15 MBq of
activity. The red box shows the region affected by spillover effect. The blue boxes are the areas affected by partial volume losses due to the small
volume of the structure.
doi:10.1371/journal.pone.0030623.g003
Figure 4. TSPO mRNA expression in bone. (A) Lanes 1 and 5 show 100 bp DNA ladders. TSPO mRNA is detected in the whole bone tissue of a
normal mouse (lane 4). Restriction enzyme assay was used to confirm the specificity of the result. PCR products of expected band sizes are produced
from the digestion by NcoI (lane 2) and PvuII (lane 3). (B) shows the expressions of TRAP, (C) the expression of ALP and (D) the expression of TSPO
mRNA in primary osteoclast and osteoblast cultures and in skeletal muscle (N = 3). OB=primary osteoblast culture from calvaria; OC=primary
osteoclast culture from spleen cells treated with M-CSF/RANKL. Error bar = standard deviation.
doi:10.1371/journal.pone.0030623.g004
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using the ‘‘Enlarge’’ tool (Figure 1B) and then the measurement of
the inverted grey values from 6 to 7 serially cut bone sections in the
isolated sub-growth plate spongiosa (Figure 1C). Grey values were
converted into Bq/mg using the tritium standards (Amersham
Biosciences, Uppsala, Sweden). Statistical analysis of intergroup
variation was carried out using one-way ANOVA followed by
Tukey’s multiple comparison test, and deemed significant at
p,0.05.
MicroPET study
Dynamic skeletal scans were performed using the microPETH
FocusTM 220 animal scanner (Preclinical Solutions, Siemens
Healthcare Molecular Imaging, Knoxville, TN, USA). This device
has a 7.6 cm axial field of view (FOV), 19 cm transaxial FOV and
resolution at the centre of the FOV of 1.4 mm. The mouse was
placed on a heating pad (38uC) to acclimatize for 20 minutes prior
to anesthetizing with 2% isoflurane in oxygen. With the animal in
a supine position, the hind legs of the mouse were spread alongside
of its body, with the tibia parallel to the long axis of the animal. A
pressure transducer was taped to its chest for monitoring
respiration throughout the scan.
No carrier added-aqueous [18F]fluoride ion produced on a
PETtrace cyclotron (GE Healthcare, Sweden), was diluted to a
concentration of approximately 30 MBq in 0.3 mL saline and
injected via the tail vein of the mouse for an 1-hour dynamic
emission scan (with a ring difference of 47 and span of 3). An
energy window of 350 to 650 keV and coincidence timing window
of 6 nanoseconds were used in all studies. No transmission scan
was performed and no attenuation or scatter correction was
applied to the data. Dead time correction, arc correction and
decay correction were applied to the acquired data prior to image
reconstruction.
Post-processing and viewing of the reconstructed images were
performed using the supplied microPET software – microPET
ASIPro VMTM 6.2.1.8 (ASIPro; Siemens Medical Solutions
U.S.A., Inc.). The 3D sinograms were reconstructed using the
MAP algorithm [23] with 18 iterations and a b value of 0.0001.
3D ROIs were drawn manually over the femur along the sagittal
planes (Figure 2A; a coronal plane of a mouse microPET
tomogram is shown in Figure 2B) of the summed image of each
Figure 5. [3H]PK11195 film autoradiography of bone. [3H]PK11195 binding in the spongiosa (sub-growth plate region) is lower in mice treated
with OPG (A), compared to mice on a low calcium diet (B) and at an intermediate level in saline-treated control mice (C).
doi:10.1371/journal.pone.0030623.g005
Figure 6. Quantification of [3H]PK11195 binding in mice with
altered bone turnover. The regional binding in the sub-growth plate
spongiosa is quantitatively expressed as tissue equivalent activities (Bq/
mg; N = 4/group). A significant difference (*) is observed between
animals with OPG and low calcium diet treatments (p = 0.01, one-way
ANOVA with Tukey’s multiple comparison test). Error bar = standard
deviation.
doi:10.1371/journal.pone.0030623.g006
Translocator Protein Expression in Bone Tissues
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30623
animal for standardized uptake values (SUVs) quantification i.e.
tissue activity uptake normalized by the injected dose per unit
weight [24]. Statistical analysis of intergroup variation (only mice
with OPG treatment and mice on a low calcium diet were used in
this experiment) was carried out using Student’s t-test, and deemed
significant at p,0.05.
Phantom design, construction and data acquisition
For simulating a mouse femur in an in vivo situation, a phantom
set was prepared using glass Pasteur pipettes filled with gelatin
(20% of 20N Grade edible gelatine; GELTA Australia Pty Ltd)
containing different levels of radioactivity (Figure 3): (1) the partial
volume phantom (1 MBq) containing 1 MBq of [18F]fluoride; (2)
the partial volume phantom (8 MBq) containing 8 MBq of
[18F]fluoride; and (3) the spillover phantom containing 8 MBq
of [18F]fluoride with an additional 15 MBq of [18F]fluoride on top.
A 360-second static emission scan was acquired of the phantoms.
The phantoms were located in the scanner such that the centre of
the field of view was positioned 4 mm from the interface between
the regions of 8 and 15 MBq of [18F]fluoride (Figure 3). The same
acquisition settings and reconstruction parameters as in the animal
study described above were used. For post-processing, a fixed
circular 2D ROI (4 mm64 mm) was drawn on each transverse
plane of the MAP reconstructed image along the long axis of each
glass Pasteur pipette. The maximum ROI value was calculated
and plotted against the plane number to produce an activity
profile.
Results and Discussion
TSPO mRNA expression in whole bone, osteoclasts and
osteoblasts
The TSPO primers used in the current study demonstrated high
specificity to the target gene. A single band of the expected size
(361 bp) was amplified from the whole bone tissue of a normal
mouse (Figure 4A, lane 4). The specificity of the product was
confirmed by restriction enzyme assay. PCR products amplified
from the whole bone tissue were digested using the selected
restriction enzymes, yielding products of the predicted band sizes,
i.e. NcoI yielded products of 116 bp and 245 bp (Figure 4A, lane
2); while PvuII digestion yielded products of 159 bp and 202 bp
(Figure 4A, lane 3). Furthermore, sequencing of the amplicon
confirmed the gene as mouse TSPO (Genbank accession number
NM_009775).
RNA isolated from whole bone demonstrated significant TSPO
gene expression. Since hematopoietic cells, such as monocytes
[25], polymorphonuclear neutrophils [26], lymphocytes [27],
platelets [11,28] and erythrocytes [29], too, express TSPO, it is
likely that some of the TSPO gene expression found in whole bone
is due to contaminating bone marrow which is difficult to fully
remove from a mouse femur of 1 mm diameter. Therefore, pure
primary osteoclasts derived from mouse spleen cells with M-CSF/
RANKL treatment and osteoblasts derived from newborn mouse
calvaria were examined for the presence of TSPO gene products.
Using TRAP and ALP as cell-type specific markers for osteoclasts
and osteoblasts, respectively, revealed that both primary TRAP-
expressing osteoclasts (Figure 4B) and ALP-expressing primary
osteoblasts (Figure 4C) express the TSPO gene (Figure 4D).
Primary osteoblasts and osteoclasts had similarly high TSPO
mRNA expression levels that were approximately 10 times higher
than that in skeletal muscle [18] (Figure 4D).
Our finding of TSPO expression in primary osteoblasts is
consistent with a previous report for human osteoblasts [9]. In
addition, we found that TSPO mRNA is also expressed in
osteoclastic cells (Figure 4D). This TSPO expression is comparable
to that seen in microglia and macrophages, that like osteoclasts are
of monocyte/phagocyte lineage [30,31].
Regional [3H]PK11195 binding in normal mouse bone
The selective ligand PK11195 binds to the TSPO with a single
high affinity [32] and, labelled with the positron-emitter [11C], has
been used to image neuroinflammatory brain pathology in vivo by
PET [12,14]. Here, we used the tritiated ligand [3H]PK11195 and
film autogradiography [12,22] to complement TSPO mRNA
expression data and show the regional expression of the TSPO
receptor in bone tissue, more specifically the highly dynamic sub-
growth plate spongiosa.
Figure 5 shows the autoradiographs of the mouse femur from
each treatment group. Dark areas of the section, representing high
levels of bound [3H]PK11195 were observed beneath the growth
plate, i.e. in the primary and secondary spongiosa (area enclosed
by the black line), and in the trabecular bone of the epiphysis. No
or negligible [3H]PK11195 binding was detected in the cortical
bone or within the growth plate itself.
The bone autoradiographs showed a marked decrease in the
trabecular bone architecture in the distal femur of the OPG-
treated mice when compared to those from mice with low calcium
diet (Figure 5A and B). Control mouse showed an intermediate
Figure 7. [18F]fluoride uptake measured by microPET. [18F]fluoride uptake is expressed in SUV for left femur (A), right femur (B) and both
femurs together (C) (N = 4/group). Error bar = standard deviation. A significant group difference between OPG-treated and low calcium diet animals
can be seen in the pooled bone data. However, the differences are small and not consistent if right and left femurs are compared separately (right
and left femurs: OPG-treated = 22.461.9; low calcium diet = 24.7361.76, p = 0.023; left femur: OPG-treated = 21.9161.74; low calcium
diet = 24.7661.47, p = 0.046; right femur: OPG-treated= 22.8962.18; low calcium diet = 24.762.25, p = 0.293).
doi:10.1371/journal.pone.0030623.g007
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level (Figure 5C). Spongiosa is mainly composed of trabeculae,
which have a greater surface area per unit bone volume than
cortical bones. Thus, trabeculae have higher turnover than cortical
bone tissue [33], particularly in mice that do not have Haversian
remodeling of cortical bone [34]. The observed distribution
pattern of [3H]PK11195 binding in bone overlaps closely the areas
in the bone that are known to have high turnover, such as the sub-
growth plate spongiosa [33].
Regional [3H]PK11195 binding levels in mouse models of
altered bone turnover
The [3H]PK11195 binding levels quantified by high resolution
film autoradiography showed differences between the three
treatment groups (3206128 Bq.mg21 for the OPG-treated group;
4996106 Bq.mg21 for the saline-treated group and 6156
90 Bq.mg21 for the low calcium diet group; p = 0.012; Figure 6).
A significant difference was found between the OPG-treated and
Figure 8. Spillover and partial volume loss phantoms. (A) The coronal [18F]fluoride microPET image shows the area of the knee joint where
spillover effect and partial volume loss occur (grey circle). The diagram shows how the phantom mimics the spillover effect and partial volume loss.
The areas of the phantom that show high partial volume loss are marked by blue boxes; the area of spillover effect is marked by a red box. (B) The
activity profiles, plotted from the narrow to the wide end of the glass Pasteur pipette, are shown for each of the phantoms. The red box region (plane
numbers 42 to 52) corresponds to the spillover effect region described in (A). The blue boxes (plane numbers 7 to 16) correspond to the partial
volume loss regions described in (A). The central plane (plane 47) of the microPET tomogram is indicated in the figure. Plane 52 is the interface
between the region of high (15 MBq) and low activity (8 Mbq).
doi:10.1371/journal.pone.0030623.g008
Translocator Protein Expression in Bone Tissues
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30623
the low calcium diet mice (p = 0.01, Tukey’s multiple comparison
test). However, the separation of the treated animals of either kind
from the saline-treated control group was too little to reach
statistical significance (Tukey’s multiple comparison test: OPG-
treated mice compared to the saline-treatment p = 0.1; low
calcium diet mice compared to the saline-treatment p = 0.33).
This suggest that despite the high spatial resolution of approxi-
mately 100 mm2 [35] achievable with film autoradiography,
[3H]PK11195 binding is unlikely to be a suitable indicator of
pathological bone turnover.
Feasibility of skeletal microPET imaging – partial volume
loss and spillover effect
There are currently few non-invasive methods for measuring
bone turnover in experimental rodent models. Despite the general
observation that TSPO expression as measured by increased
PK11195 binding correlates well with the presence of tissue
pathology in many different organs and can also be observed in
altered bone turnover, our tissue binding data suggest that the
differences in bone measured by [3H]PK11195 are small. It,
therefore, remains to be shown whether carbon-11 labelled
PK11195 provides a better signal-to-noise ratio and may be a
feasible radioligand for microPET imaging of bone. In contrast,
[18F]fluoride is already known to have high uptake in bone and
thus give rise to a high signal in microPET. Therefore, in order to
establish the capability of microPET to measure changes in bone
turnover, we imaged mice femur with differentially altered bone
turnover. The femur being a large bone is the best region to study
since in thinner bones blood activity and unbound [18F]fluoride
tend to cause confounding effects [36].
In this microPET study, OPG-treated mice were compared to
low calcium diet mice, i.e. the groups that have been shown to
have the largest difference in bone turnover. The microPET
tomogram showed the expected high fluoride uptake in the
skeleton with highest uptake in the distal and proximal metaphyses
of the main long bones (Figure 2B). These regions correspond to
areas of rapid bone growth and probably reflect the rapid
mineralization occurring in hypertrophic cartilage of the growth
plates and bone formation in the primary and secondary
spongiosa. However, microPET using [18F]fluoride only revealed
subtle and not fully consistent differences between OPG-treated
mice and low calcium diet mice (Figure 7) (right and left femurs:
OPG-treated = 22.461.9; low calcium diet = 24.7361.76,
p = 0.023; left femur: OPG-treated = 21.9161.74; low calcium
diet = 24.7661.47, p = 0.046; right femur: OPG-treat-
ed = 22.8962.18; low calcium diet = 24.762.25, p = 0.293).
The failure of [18F]fluoride-microPET in showing fully
consistent differences between animals with low and high bone
turnover may have a number of biological and methodological
reasons. An obvious reason warranting separate investigation
relates to limitations in instrument sensitivity and resolution, which
would cause marked spillover effect [37] and partial volume loss
[38]. To conclude the feasibility study of [18F]fluoride-microPET,
a phantom set was designed to replicate the extent to which the
spillover effect and partial volume loss suggested by mouse bone
microPET datasets are indeed the case (Figure 8).
Spillover effect at the femoral head is likely to be caused by the
adjacent tibial head. In our phantom, a high activity gelatin
source placed adjacent to a low activity gelatin mimics the effect
of the adjacent tibial head (Figure 8A and B – the regions
enclosed by the red circles/box). In contrast, partial volume loss is
expected to be significant in the region of the mouse mid-femur
and is mimicked in our study by the narrow end of a glass Pasteur
pipette with a diameter of ,1 mm, which is the same as a mouse
mid-femur (Figure 8A and B – the regions enclosed by the blue
circle/boxes), Unlike in the spillover phantom, the activity within
the partial volume phantoms is homogenous, i.e. any effects are
purely due to variation in volume. The mouse microPET data
indicated a ratio of activity at the distal femur to mid-femur of
approximately 1 to 8. This activity ratio was reproduced in our
phantom (Figure 8A).
The activity profile of our spillover phantom measured by
microPET confirmed the presence of significant spillover effect
(Figure 8B). Depending on the distance from to the high activity
region causing the spillover effect, the actual measured activity in
the region of low activity was approximately 4% to 112% higher
than the true activities in the phantom (Table 1).
The activity profiles of our partial volume phantoms (Figure 8B)
demonstrated that the measured activity in small ROIs is
approximately 55 to 70% below the true activity values (Table 2).
Small volumes with low activity show relatively more partial
volume loss than small volumes with high activity.
Table 1. Spillover effect on a region with low activity.
Reconstruction
algorithm
Plane
number
Spillover phantom
profile (kBq/ml)
Partial volume phantom
(8 MBq) profile (kBq/ml)
% increase due
to spillover
MAP 42 291.7 280.85 3.86
43 324.26 292.67 10.79
44 363.28 297.61 22.07
45 416.2 307.11 35.52
46 467.12 312.59 49.44
47 537.21 327.46 64.05
48 607.56 334.43 81.67
49 670.57 341.19 96.54
50 729.26 354.79 105.55
51 761.89 358.59 112.47
52 789.88 372.66 111.95
The table shows the plane-by-plane false high measurements due to spillover from a region of high activity (15 MBq) into an area of low activity (8 MBq). The error
ranges from approximately 4% to 112% depending on the proximity to the region of high activity.
doi:10.1371/journal.pone.0030623.t001
Translocator Protein Expression in Bone Tissues
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30623
In summary, the phantom modeled in dimension and activity
on the actual bone uptake data in our [18F]fluoride microPET,
suggests that spillover effect and partial volume loss are a likely
major cause why the expected biological variations in our animal
models of altered bone turnover could not be adequately detected.
Conclusion
Our study shows that, like in other organ systems, there is a
significant expression of the TSPO in bone tissue and that the
expression levels of TSPO relate to active tissue changes. The
exact role of the TSPO in physiological and pathological bone
turnover remains to be studied. However, there are now a number
of pharmacologically active ligands for the TSPO available. These
are so far used for other purposes such as anxiolysis [39,40], and
their effects on bone are not known. The turnover dependent
presence of TSPO in bone provides a rational to study the TSPO
as potential therapeutic target in diseased bone.
While in vivo molecular imaging of bone to measure the cellular
correlates of bone pathology is desirable, the available instrumen-
tation and radioligands require further refinement to undertake
systematic studies in experimental animal models.
Supporting Information
Table S1 PCR primers. Primer sequences for PCR amplifi-
cation of TSPO, ALP, TRAP and GAPDH genes.
(DOC)
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